Eli Lilly: Still Much Room To Ride The Weight-Loss Wave

Investment Opportunities - Novo Nordisk (NVO) is currently undervalued, presenting a near-term bullish opportunity [1] - Eli Lilly (NYSE: LLY) also offers an exceptional investment opportunity at present [1] Analyst Background - Oliver Rodzianko is an investment analyst specializing in the technology sector, with expertise in AI, semiconductors, software, and renewable energy [1] - Rodzianko focuses on companies with resilient management and lasting competitive advantages [1] - His investment strategy involves value trading at inflection points without leverage and without short interest, typically holding investments for one to two years [1] - Rodzianko employs advanced risk-mitigation strategies to protect against and capitalize on recessions and market crashes [1]